USPTO Examiner MENDEZ MANUEL A - Art Unit 3783

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19028890DRUG DELIVERY DEVICE WITH FEEDBACK MECHANISMJanuary 2025March 2025Allow200NoNo
19000461Smart IV Pole: An Integrated Solution for Medical Device Connectivity, Patient Monitoring, and CommunicationDecember 2024May 2025Allow410YesNo
18968283DOSING OF INCRETIN PATHWAY DRUGSDecember 2024May 2025Allow510NoNo
18960470Medicament Container Carrier and AdapterNovember 2024June 2025Allow601NoNo
18960071Medicament Container Carrier and AdapterNovember 2024February 2025Allow300NoNo
18957952Medicament Container Carrier and AdapterNovember 2024June 2025Allow601NoNo
18806797INTEGRATED INSULIN DELIVERY SYSTEM WITH CONTINUOUS GLUCOSE SENSORAugust 2024April 2025Allow811YesNo
18785610INTEGRATED INSULIN DELIVERY SYSTEM WITH CONTINUOUS GLUCOSE SENSORJuly 2024September 2024Allow200NoNo
18735124METHOD AND SYSTEM FOR TUNING HORMONE RECEPTORS THROUGH THE DYNAMIC INTRAVENOUS DELIVERY OF A HORMONE ACCORDING TO A TARGET PHYSIOLOGICAL CADENCEJune 2024October 2024Allow510YesNo
18599791Medicament Container Carrier and AdapterMarch 2024May 2024Allow300NoNo
18428921BLOOD GLUCOSE SENSING SYSTEMJanuary 2024August 2024Allow710YesNo
18426297LIQUID MEDICINE INJECTION DEVICEJanuary 2024May 2024Allow300NoNo
18407094COMBINED NEEDLE AND CANNULAJanuary 2024October 2024Abandon910NoNo
18390338AUTOMATICALLY OR MANUALLY INITIATED MEAL BOLUS DELIVERY WITH SUBSEQUENT AUTOMATIC SAFETY CONSTRAINT RELAXATIONDecember 2023May 2024Allow510NoNo
18538438IMPLANTABLE CELLULAR AND BIOTHERAPEUTIC AGENT DELIVERY CANISTERDecember 2023December 2024Allow1220NoNo
18482596INSULIN MANAGEMENTOctober 2023February 2024Allow410YesNo
18373558SYSTEMS AND METHODS FOR COACHING INHALER USE VIA SYNCHRONIZING PATIENT AND RESPIRATORY CYCLE BEHAVIORSSeptember 2023December 2023Allow300NoNo
18235091BIOINTEGRATIVE IMPLANTABLE CELL ENCAPSULATION DEVICE AND SYSTEMAugust 2023May 2024Allow900NoNo
18325564METHOD, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR CGM-BASED PREVENTION OF HYPOGLYCEMIA VIA HYPOGLYCEMIA RISK ASSESSMENT AND SMOOTH REDUCTION INSULIN DELIVERYMay 2023January 2024Allow820NoNo
18316703TECHNIQUES TO REDUCE RISK OF OCCLUSIONS IN DRUG DELIVERY SYSTEMSMay 2023March 2025Allow2200NoNo
18314791REAL-TIME MEAL DETECTION BASED ON SENSOR GLUCOSE AND ESTIMATED PLASMA INSULIN LEVELSMay 2023July 2023Allow200NoNo
18310731APPARATUS AND METHOD FOR SENSOR DEPLOYMENT AND FIXATIONMay 2023June 2025Allow2510NoNo
18033137METHOD FOR CONTROLLING ARTIFICIAL PANCREAS INCLUDING INSULIN PATCH AND DEVICE THEREFORApril 2023November 2023Allow700NoNo
18304117INFUSION PUMP SYSTEM AND METHODSApril 2023October 2023Allow610NoNo
18295015Insulin ManagementApril 2023June 2023Allow300NoNo
18190678ACTIVITY MODE FOR ARTIFICIAL PANCREAS SYSTEMMarch 2023June 2025Allow2710NoNo
18122012Acoustic Method for Precisely Controlling and Metering the Manual Injection DosageMarch 2023November 2023Allow810NoNo
18119650IV FLOW MANAGEMENT SYSTEMS AND METHODSMarch 2023May 2025Allow2710NoNo
18116962LIQUID MEDICINE INJECTION DEVICEMarch 2023October 2023Allow800NoNo
18176532SYSTEMS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTSMarch 2023May 2024Allow1410NoNo
18114961ASSEMBLIES, SYSTEMS AND METHODS FOR PROGRAMMING MEDICAL DEVICESFebruary 2023May 2024Allow1510YesNo
18108195MULTIPLE USE DISPOSABLE INJECTION PENFebruary 2023February 2025Allow2400NoNo
18161226INTEGRATED VASCULAR DELIVERY SYSTEMJanuary 2023April 2025Allow2610NoNo
18067417PREDICTION BASED DELIVERING OR GUIDING OF THERAPY FOR DIABETESDecember 2022March 2025Allow2710NoNo
18066517METHOD FOR FABRICATING WEARABLE HYDROGEL GLUCOSE SENSORDecember 2022July 2023Allow700NoNo
18066790INJECTION MONITORING DEVICEDecember 2022March 2025Allow2710NoNo
18078346DEVICE AND METHOD FOR DELIVERING A MEDICAMENTDecember 2022January 2025Allow2600NoNo
18072207LOW CONCENTRATION DELIVERY OF AN ERGOLINE DERIVATIVE FOR TREATMENT OF A HEADACHENovember 2022May 2025Allow2910NoNo
18058041SYSTEMS AND METHODS FOR DELIVERING MICRODOSES OF MEDICATIONNovember 2022February 2023Allow300NoNo
17984100PRE-CONNECTED ANALYTE SENSORSNovember 2022April 2025Abandon2910NoNo
17972117IMPLANTABLE CELLULAR AND BIOTHERAPEUTIC AGENT DELIVERY CANISTEROctober 2022August 2023Allow1011NoNo
17935483TECHNIQUES ENABLING ADAPTATION OF PARAMETERS IN AID SYSTEMS BY USER INPUTSeptember 2022April 2023Allow610YesNo
17933249SYSTEM AND METHOD FOR ADJUSTING INSULIN DELIVERYSeptember 2022February 2025Allow2910YesNo
17821150DYNAMIC FORECASTSAugust 2022December 2024Allow2800NoNo
17818504USER PARAMETER DEPENDENT COST FUNCTION FOR PERSONALIZED REDUCTION OF HYPOGLYCEMIA AND/OR HYPERGLYCEMIA IN A CLOSED LOOP ARTIFICIAL PANCREAS SYSTEMAugust 2022June 2025Allow3410NoNo
17884508EXOSKELETON DEVICE WITH EXPANDABLE SECTION FOR SCORINGAugust 2022March 2025Allow3110YesNo
17818136Systems and Methods for Monitoring and Controlling Fluid Infusion to a PatientAugust 2022October 2024Allow2600NoNo
17878217INFUSION DEVICE SYSTEM AND APPARATUSAugust 2022May 2025Allow3311NoNo
17876862MEDICAMENT DELIVERY DEVICEJuly 2022December 2024Allow2800NoNo
17759512METHOD AND APPARATUS FOR DISPLAYING PROGRESS INFORMATIONJuly 2022June 2025Allow3500NoNo
17851068Method and System of Remote Control and Remote Monitor in Treating Respiratory PatientsJune 2022October 2022Allow410NoNo
17843631Feedback Mechanism for an Injection DeviceJune 2022March 2025Abandon3310NoNo
17842564Fluid Delivery and Measurement Systems and MethodsJune 2022May 2025Abandon3510NoNo
17841042LOW CONCENTRATION DELIVERY OF AN ERGOLINE DERIVATIVE FOR TREATMENT OF A HEADACHEJune 2022October 2022Allow410NoNo
17831189RADIAL AND TRANS-ENDOCARDIAL DELIVERY CATHETERJune 2022April 2025Allow3410NoNo
17752236OPTIMIZING EMBEDDED FORMULATIONS FOR DRUG DELIVERYMay 2022May 2025Allow3610NoNo
17756232LIQUID DELIVERY DEVICE AND METHODMay 2022April 2025Allow3500NoNo
17744607CONTEXT-SENSITIVE INFUSION DEVICES, SYSTEMS AND METHODSMay 2022December 2024Allow3110NoNo
17737107Data Collection Device for Attachment to an Injection DeviceMay 2022October 2024Allow2900NoNo
17736813Methods and Devices for Burden-free Blood Glucose Management With Minimal User InteractionMay 2022January 2025Allow3210NoNo
17736825Methods and Devices for Minimally Burdensome Blood Glucose Management for Insulin-requiring DiabetesMay 2022November 2024Allow3110NoNo
17732771METHOD AND DEVICE FOR HAIR LOSS PREDICTION AND PERSONALIZED SCALP CAREApril 2022August 2022Allow400NoNo
17728221OPIOID MANAGEMENT SYSTEMApril 2022November 2024Allow3010NoNo
17771069SYSTEM FOR INTERROGATING SERIALLY-CONNECTED DRUG MODULES IN A COMBINATORIAL DRUG DELIVERY DEVICEApril 2022May 2025Allow3600NoNo
17725202DEVICE AND METHOD FOR DELIVERING A MEDICAMENTApril 2022September 2024Allow2900NoNo
17719224PRE-CONNECTED ANALYTE SENSORSApril 2022December 2022Abandon910NoNo
17719181PRE-CONNECTED ANALYTE SENSORSApril 2022September 2022Allow510NoNo
17718156BREAST PUMP MILK FLOW RATE SENSOR SYSTEM AND APPARATUSApril 2022October 2024Allow3110NoNo
17715589COMPENSATION FOR MISSING READINGS FROM A GLUCOSE MONITOR IN AN AUTOMATED INSULIN DELIVERY SYSTEMApril 2022October 2024Allow3010NoNo
17713800Systems and Methods for Regulating Fluid Infusion in a PatientApril 2022July 2024Allow2700NoNo
17657086CLOUD-CONNECTED AMBULATORY PUMP INTEGRATIONMarch 2022August 2022Allow400NoNo
17690755Personal medical device for administering treatment via mucous membraneMarch 2022November 2023Allow2021NoNo
17687808ADAPTIVE UPDATE OF AUTOMATIC INSULIN DELIVERY (AID) CONTROL PARAMETERSMarch 2022April 2025Allow3710NoNo
17687201BASAL TITRATION WITH ADAPTIVE TARGET GLUCOSE LEVELMarch 2022July 2024Allow2800NoNo
17653170MEDICAMENT PUMPS AND CONTROL SYSTEMS FOR MANAGING GLUCOSE CONTROL THERAPY DATA OF A SUBJECTMarch 2022August 2022Allow500NoNo
17685235AMBULATORY MEDICAMENT DEVICE WITH MOTION DETECTION AND GESTURE-BASED CONTROLMarch 2022March 2023Allow1210NoNo
17653088INFUSION PUMP WITH SAFETY SEQUENCE KEYPADMarch 2022January 2025Allow3410NoNo
17652448SYSTEMS AND METHODS FOR DELIVERING MICRODOSES OF MEDICATIONFebruary 2022September 2022Allow710NoNo
17670967SYSTEM AND METHOD FOR IMPROVING THE DRUG THERAPY MANAGEMENTFebruary 2022August 2024Allow3010NoNo
17671227INFUSION PUMP SYSTEM AND METHOD WITH COMMON LINE AUTO FLUSHFebruary 2022June 2024Allow2800NoNo
17668687CUSHION FOR MASK SYSTEMFebruary 2022December 2024Abandon3510NoNo
17584748IMPLANTABLE CELLULAR AND BIOTHERAPEUTIC AGENT DELIVERY CANISTERJanuary 2022August 2023Allow1911NoNo
17575306SYSTEM AND METHOD FOR SWITCHING BETWEEN MEDICAMENT DELIVERY CONTROL ALGORITHMSJanuary 2022July 2024Allow3100NoNo
17569528Facilitating Remote Control Of Oxygen SupplyJanuary 2022May 2022Allow400NoNo
17566840ANTIARRHYTHMIC DRUG DOSING METHODS, MEDICAL DEVICES, AND SYSTEMSDecember 2021July 2022Allow710NoNo
17646598CONTEXTUAL ADJUSTMENT OF CONTROL PARAMETERSDecember 2021September 2024Allow3310NoNo
17645693CONTEXTUAL ADJUSTMENT OF INSULIN ABSORPTION CURVESDecember 2021April 2024Allow2800NoNo
17556574OPTIMIZED INTRATHECAL DRUG DELIVERYDecember 2021July 2024Allow3110NoNo
17554978Rapidly Insertable Central Catheters, Assemblies, And Methods ThereofDecember 2021July 2024Allow3110YesNo
17596591ULTRASOUND-INDUCED POSITIONING TYPE PUNCTURE ASSEMBLY AND SLEEVE TYPE SMALL NEEDLE KNIFEDecember 2021May 2025Allow4210NoNo
17549935Model-Based Personalization Scheme of an Artificial Pancreas for Type I Diabetes ApplicationsDecember 2021May 2024Allow2910NoNo
17550458Systems and Methods for Monitoring and Controlling Fluid Infusion to a PatientDecember 2021April 2022Allow400NoNo
17548023DERMAL SPRAY APPARATUS AND METHODDecember 2021May 2022Allow610YesNo
17541673DETERMINATION OF ADJUSTMENTS TO FLUID DELIVERY SETTINGSDecember 2021July 2024Allow3110NoNo
17539270OPTIMIZING EMBEDDED FORMULATIONS FOR DRUG DELIVERYDecember 2021February 2022Allow300NoNo
17534323EXOSKELETON DEVICE WITH EXPANDABLE SECTION FOR SCORINGNovember 2021July 2024Allow3210NoNo
17526428MEDICAL BALLOONNovember 2021December 2024Allow3711YesNo
17526154MULTI-LANGUAGE / MULTI-PROCESSOR INFUSION PUMP ASSEMBLYNovember 2021June 2024Allow3110NoNo
17517368Stabilizing Connector Devices for Vascular Access and Methods of Using the SameNovember 2021July 2024Allow3210NoNo
17513941INFUSION OF DRUGSOctober 2021March 2024Allow2900NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MENDEZ, MANUEL A.

Strategic Value of Filing an Appeal

Total Appeal Filings
12
Allowed After Appeal Filing
5
(41.7%)
Not Allowed After Appeal Filing
7
(58.3%)
Filing Benefit Percentile
67.1%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 41.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner MENDEZ, MANUEL A - Prosecution Strategy Guide

Executive Summary

Examiner MENDEZ, MANUEL A works in Art Unit 3783 and has examined 710 patent applications in our dataset. With an allowance rate of 93.2%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 29 months.

Allowance Patterns

Examiner MENDEZ, MANUEL A's allowance rate of 93.2% places them in the 80% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MENDEZ, MANUEL A receive 1.05 office actions before reaching final disposition. This places the examiner in the 14% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MENDEZ, MANUEL A is 29 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +6.7% benefit to allowance rate for applications examined by MENDEZ, MANUEL A. This interview benefit is in the 35% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 33.3% of applications are subsequently allowed. This success rate is in the 66% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 65.5% of cases where such amendments are filed. This entry rate is in the 87% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 76% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 99% percentile among all examiners. Of these withdrawals, 63.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 20.1% are granted (fully or in part). This grant rate is in the 11% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 3.8% of allowed cases (in the 86% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 25.4% of allowed cases (in the 94% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.